What Evidence Do We Need For Biomarker Qualification?

Chris Leptak,Joseph P Menetski,John A Wagner,Jiri Aubrecht, Linda Brady,Martha Brumfield,William W Chin,Steve Hoffmann,Gary Kelloff, Gabriela Lavezzari, Rajesh Ranganathan, John-Michael Sauer,Frank D Sistare, Tanja Zabka,David Wholley

SCIENCE TRANSLATIONAL MEDICINE(2017)

引用 54|浏览29
暂无评分
摘要
Biomarkers can facilitate all aspects of the drug development process. However, biomarker qualification-the use of a biomarker that is accepted by the U.S. Food and Drug Administration-needs a clear, predictable process. We describe a multistakeholder effort including government, industry, and academia that proposes a framework for defining the amount of evidence needed for biomarker qualification. This framework is intended for broad applications across multiple biomarker categories and uses.
更多
查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要